Your browser doesn't support javascript.
loading
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero, Josep; Yoshino, Takayuki; Cohn, Allen Lee; Obermannova, Radka; Bodoky, Gyorgy; Garcia-Carbonero, Rocio; Ciuleanu, Tudor-Eliade; Portnoy, David C; Van Cutsem, Eric; Grothey, Axel; Prausová, Jana; Garcia-Alfonso, Pilar; Yamazaki, Kentaro; Clingan, Philip R; Lonardi, Sara; Kim, Tae Won; Simms, Lorinda; Chang, Shao-Chun; Nasroulah, Federico.
Afiliação
  • Tabernero J; Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: jtabernero@vhio.net.
  • Yoshino T; Department of Gastroenterology, National Cancer Centre Hospital East, Chiba, Japan.
  • Cohn AL; Rocky Mountain Cancer Center/US Oncology, Denver, CO, USA.
  • Obermannova R; Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
  • Bodoky G; Department of Oncology, Szent László Hospital, Budapest, Hungary.
  • Garcia-Carbonero R; Hospital Universitario Virgen del Rocio, Instituto de Biomedicina de Sevilla, RTICC, Instituto Carlos III, Spanish Ministry of Science and Innovation, Seville, Spain.
  • Ciuleanu TE; Prof Dr Ion Chiricuta Institute of Oncology and UMF Iuliu Hatieganu, Cluj-Napoca, Romania.
  • Portnoy DC; West Clinic, Memphis, TN, USA.
  • Van Cutsem E; University Hospitals Gasthuisberg, Leuven, Belgium.
  • Grothey A; Department of Oncology, Mayo Clinic, Rochester, MN, USA.
  • Prausová J; University Hospital Motol, Prague, Czech Republic.
  • Garcia-Alfonso P; Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Yamazaki K; Shizuoka Cancer Centre, Shizuoka, Japan.
  • Clingan PR; Southern Medical Day Care Centre, Wollongong, NSW, Australia.
  • Lonardi S; Medical Oncology 1, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
  • Kim TW; Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea.
  • Simms L; Eli Lilly Canada, Toronto, ON, Canada.
  • Chang SC; Eli Lilly, Indianapolis, IN, USA.
  • Nasroulah F; Eli Lilly and Company, Bridgewater, NJ, USA.
Lancet Oncol ; 16(5): 499-508, 2015 May.
Article em En | MEDLINE | ID: mdl-25877855
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos Organoplatínicos / Camptotecina / Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Anticorpos Monoclonais Humanizados / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos Organoplatínicos / Camptotecina / Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Anticorpos Monoclonais Humanizados / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article